NeurogesX Reports Results From Second Postherpetic Neuralgia Trial

September 4, 2007

NeurogesX announced positive topline results from its second Phase III study of NGX-4010, the company’s dermal patch containing synthetic capsaicin in patients with postherpetic neuralgia.

The multicenter, double-blind, controlled Phase III trial evaluated 416 patients in the U.S. and Canada.  According to NeurogesX, patients on NGX-4010 demonstrated a 32 percent reduction in pain from baseline from a single 60-minute application of NGX-4010 as compared with a 24 percent reduction in the control group.

The company added that it remains on track to complete the filing of a marketing authorization application this year for European regulatory approval of NGX-4010. It also expects to submit an new drug application with the FDA in the second half of 2008 for both postherpetic neuralgia and HIV-distal sensory polyneuropathy.